{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:15:34Z","timestamp":1789643734149,"version":"4.0.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Over than one third (28\u201358%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However, FDA has categorized Trastuzumab as a category D drug for pregnant patients with breast cancer. This systemic review aims to synthesize all currently available data of trastuzumab administration during pregnancy and provide an updated view of the effect of trastuzumab on fetal and maternal outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eligible articles were identified by a search of MEDLINE bibliographic database and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      for the period up to 01\/09\/2020; The algorithm consisted of a predefined combination of the words \u201cbreast\u201d, \u201ccancer\u201d, \u201ctrastuzumab\u201d and \u201cpregnancy\u201d. This study was performed in accordance with the PRISMA guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 28 eligible studies were identified (30 patients, 32 fetuses). In more than half of cases, trastuzumab was administered in the metastatic setting. The mean duration of trastuzumab administration during gestation was 15.7\u2009weeks (SD: 10.8; median: 17.5; range: 1\u201332). Oligohydramnios or anhydramnios was the most common (58.1%) adverse event reported in all cases. There was a statistically significant decrease in oligohydramnios\/anhydramnios incidence in patients receiving trastuzumab only during the first trimester (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.026, Fisher\u2019s exact test). In 43.3% of cases a completely healthy neonate was born. 41.7% of fetuses exposed to trastuzumab during the second and\/or third trimester were born completely healthy versus 75.0% of fetuses exposed exclusively in the first trimester. All mothers were alive at a median follow-up of 47.0\u2009months (ranging between 9 and 100\u2009months). Of note, there were three cases (10%) of cardiotoxicity and decreased ejection fraction during pregnancy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, treatment with trastuzumab should be postponed until after delivery, otherwise pregnancy should be closely monitored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08162-3","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T06:06:17Z","timestamp":1619417177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Trastuzumab administration during pregnancy: an update"],"prefix":"10.1186","volume":"21","author":[{"given":"Angeliki","family":"Andrikopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleoniki","family":"Apostolidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridoula","family":"Chatzinikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyfalia","family":"Bletsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"8","key":"8162_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ejso.2008.01.029","volume":"34","author":"I Navrozoglou","year":"2008","unstructured":"Navrozoglou I, Vrekoussis T, Kontostolis E, Dousias V, Zervoudis S, Stathopoulos EN, et al. Breast cancer during pregnancy: a mini-review. Eur J Surg Oncol. 2008;34(8):837\u201343. https:\/\/doi.org\/10.1016\/j.ejso.2008.01.029.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"8162_CR2","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/annonc\/mdi388","volume":"16","author":"AE Ring","year":"2005","unstructured":"Ring AE, Smith IE, Ellis PA. Breast cancer and pregnancy. Ann Oncol. 2005;16(12):1855\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdi388.","journal-title":"Ann Oncol"},{"issue":"8","key":"8162_CR3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/1097-0142(19930415)71:8<2499::AID-CNCR2820710812>3.0.CO;2-S","volume":"71","author":"RM Elledge","year":"1993","unstructured":"Elledge RM, Ciocca DR, Langone G, McGuire WL. Estrogen receptor, progesterone receptor, and HER-2\/neu protein in breast cancers from pregnant patients. Cancer. 1993;71(8):2499\u2013506. https:\/\/doi.org\/10.1002\/1097-0142(19930415)71:8<2499::AID-CNCR2820710812>3.0.CO;2-S.","journal-title":"Cancer."},{"issue":"5","key":"8162_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/cncr.11614","volume":"98","author":"LP Middleton","year":"2003","unstructured":"Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98(5):1055\u201360. https:\/\/doi.org\/10.1002\/cncr.11614.","journal-title":"Cancer"},{"key":"8162_CR5","doi-asserted-by":"publisher","unstructured":"Shousha S. Breast carcinoma presenting during or shortly after pregnancy and lactation. Arch Pathol Lab Med. 2000;124. https:\/\/doi.org\/10.1043\/0003-9985(2000)124<1053:BCPDOS>2.0.CO;2.","DOI":"10.1043\/0003-9985(2000)124<1053:BCPDOS>2.0.CO;2"},{"issue":"20","key":"8162_CR6","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2012.45.6335","volume":"31","author":"F Amant","year":"2013","unstructured":"Amant F, Von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31(20):2532\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.45.6335.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8162_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/PPO.0b013e3181ce46f9","volume":"16","author":"E Cardonick","year":"2010","unstructured":"Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16(1):76\u201382. https:\/\/doi.org\/10.1097\/PPO.0b013e3181ce46f9.","journal-title":"Cancer J"},{"issue":"2","key":"8162_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdf039","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13(2):273\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdf039.","journal-title":"Ann Oncol"},{"issue":"6924","key":"8162_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin fab. Nature. 2003;421(6924):756\u201360. https:\/\/doi.org\/10.1038\/nature01392.","journal-title":"Nature."},{"key":"8162_CR10","unstructured":"Herceptin 150mg Powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc). https:\/\/www.medicines.org.uk\/emc\/product\/3856\/smpc#gref. Accessed 12 Nov 2020."},{"issue":"2","key":"8162_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10549-012-2368-y","volume":"137","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(2):349\u201357. https:\/\/doi.org\/10.1007\/s10549-012-2368-y.","journal-title":"Breast Cancer Res Treat"},{"key":"8162_CR12","doi-asserted-by":"publisher","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: Journal of clinical epidemiology. J Clin Epidemiol; 2009. p. e1\u201334. doi:https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.006.","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"issue":"06","key":"8162_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1055\/a-0880-9295","volume":"79","author":"SS Goller","year":"2019","unstructured":"Goller SS, Markert UR, Fr\u00f6hlich K. Trastuzumab in the treatment of pregnant breast Cancer patients - an overview of the literature. Geburtshilfe Frauenheilkd. 2019;79(06):618\u201325. https:\/\/doi.org\/10.1055\/a-0880-9295.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"24","key":"8162_CR14","doi-asserted-by":"publisher","first-page":"S603","DOI":"10.4103\/2152-7806.189730","volume":"7","author":"A Sharma","year":"2016","unstructured":"Sharma A, Nguyen HS, Lozen A, Sharma A, Mueller W. Brain metastases from breast cancer during pregnancy. Surg Neurol Int. 2016;7(24):S603\u20136. https:\/\/doi.org\/10.4103\/2152-7806.189730.","journal-title":"Surg Neurol Int"},{"issue":"4","key":"8162_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/1078155209103096","volume":"15","author":"PG Morris","year":"2009","unstructured":"Morris PG, King F, Kennedy MJ. Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case series. J Oncol Pharm Pract. 2009;15(4):241\u20137. https:\/\/doi.org\/10.1177\/1078155209103096.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"8162_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000341383","volume":"7","author":"C Pirvulescu","year":"2012","unstructured":"Pirvulescu C, Mau C, Schultz H, Sperfeld A, Isbruch A, Renner-L\u00fctzkendorf H, et al. Breast cancer during pregnancy: an interdisciplinary approach in our institution. Breast Care. 2012;7(4):311\u20134. https:\/\/doi.org\/10.1159\/000341383.","journal-title":"Breast Care."},{"issue":"32","key":"8162_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1556\/OH.2010.28886","volume":"151","author":"B Sz\u00e9kely","year":"2010","unstructured":"Sz\u00e9kely B, Langm\u00e1r Z, Somlai K, Szentm\u00e1rtoni G, Szalay K, Korompay A, et al. A v\u00e1rand\u00f3ss\u00e1g alatti emlor\u00e1k kezel\u00e9se. Orv Hetil. 2010;151(32):1299\u2013303. https:\/\/doi.org\/10.1556\/OH.2010.28886.","journal-title":"Orv Hetil"},{"key":"8162_CR18","unstructured":"Yukiko Hazama, Yuichiro Nakai, Shiori Sugawara, Tsunehisa Nomura, Keiko Matsumoto, Ryou Matsumoto, et al. [A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy] - PubMed. Gan To Kagaku Ryoho . 2018;45:847\u201350. https:\/\/pubmed.ncbi.nlm.nih.gov\/30026449\/. Accessed 12 Nov 2020."},{"issue":"2","key":"8162_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.reprotox.2007.11.004","volume":"25","author":"P Berveiller","year":"2008","unstructured":"Berveiller P, Mir O, Sauvanet E, Antoine EC, Goldwasser F. Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod Toxicol. 2008;25(2):286\u20138. https:\/\/doi.org\/10.1016\/j.reprotox.2007.11.004.","journal-title":"Reprod Toxicol"},{"issue":"1","key":"8162_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-012-1996-6","volume":"133","author":"HA Azim","year":"2012","unstructured":"Azim HA, Metzger-Filho O, De Azambuja E, Loibl S, Focant F, Gresko E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012;133(1):387\u201391. https:\/\/doi.org\/10.1007\/s10549-012-1996-6.","journal-title":"Breast Cancer Res Treat"},{"key":"8162_CR21","doi-asserted-by":"publisher","unstructured":"Shweta Gupta, Prantesh Jain, Susan McDunn. Breast cancer with brain metastases in pregnancy - PubMed. J Community Support Oncol. 2014;12(10):378\u201380. https:\/\/doi.org\/10.12788\/jcso.0081.","DOI":"10.12788\/jcso.0081"},{"key":"8162_CR22","unstructured":"Diakit\u00e9 K, Bouzid N, Zabroug S, Darfaoui M, Eddaoualline H, Ismaili N, Lalya I, Elomrani A, Belbaraka R, Kouchani M. The fetal toxicity of trastuzumab (herceptin) during a twin pregnancy in breast cancer: about a case. World J Pharm Med Res. 2019;5(3):187\u20138."},{"key":"8162_CR23","unstructured":"A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00833963."},{"issue":"8","key":"8162_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/CAD.0000000000000658","volume":"29","author":"N Yildirim","year":"2018","unstructured":"Yildirim N, Bahceci A. Use of pertuzumab and trastuzumab during pregnancy. Anti-Cancer Drugs. 2018;29(8):810\u20133. https:\/\/doi.org\/10.1097\/CAD.0000000000000658.","journal-title":"Anti-Cancer Drugs"},{"issue":"02","key":"8162_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0035-1559647","volume":"220","author":"R Rasenack","year":"2016","unstructured":"Rasenack R, Gaupp N, Rautenberg B, Stickeler E, Pr\u00f6mpeler H. Fallbericht einer Trastuzumab-Therapie w\u00e4hrend der Schwangerschaft bei metastasiertem Mammakarzinom. Z Geburtshilfe Neonatol. 2016;220(02):81\u20133. https:\/\/doi.org\/10.1055\/s-0035-1559647.","journal-title":"Z Geburtshilfe Neonatol"},{"issue":"3","key":"8162_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1447-0756.2011.01745.x","volume":"38","author":"S El-Safadi","year":"2012","unstructured":"El-Safadi S, Wuesten O, Muenstedt K. Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res. 2012;38(3):589\u201392. https:\/\/doi.org\/10.1111\/j.1447-0756.2011.01745.x.","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"8162_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1479-828X.2011.01314.x","volume":"51","author":"CL Mandrawa","year":"2011","unstructured":"Mandrawa CL, Stewart J, Fabinyi GC, Walker SP. A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust New Zeal J Obstet Gynaecol. 2011;51(4):372\u20136. https:\/\/doi.org\/10.1111\/j.1479-828X.2011.01314.x.","journal-title":"Aust New Zeal J Obstet Gynaecol"},{"issue":"4","key":"8162_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1258\/jrsm.2009.090260","volume":"103","author":"NJ Roberts","year":"2010","unstructured":"Roberts NJ, Auld BJ. Trastuzamab (Herceptin\u00ae)-related cardiotoxicity in pregnancy. J R Soc Med. 2010;103(4):157\u20139. https:\/\/doi.org\/10.1258\/jrsm.2009.090260.","journal-title":"J R Soc Med"},{"issue":"1","key":"8162_CR29","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.ajog.2009.02.017","volume":"201","author":"JMA Beale","year":"2009","unstructured":"Beale JMA, Tuohy J, McDowell SJ. Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol. 2009;201(1):e13\u20134. https:\/\/doi.org\/10.1016\/j.ajog.2009.02.017.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"8162_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/01443610802643774","volume":"29","author":"Q Warraich","year":"2009","unstructured":"Warraich Q, Smith N. Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol (Lahore). 2009;29(2):147\u20138. https:\/\/doi.org\/10.1080\/01443610802643774.","journal-title":"J Obstet Gynaecol (Lahore)"},{"issue":"9","key":"8162_CR31","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1200\/JCO.2008.16.0309","volume":"26","author":"S Pant","year":"2008","unstructured":"Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol. 2008;26(9):1567\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.16.0309.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8162_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/annonc\/mdm542","volume":"19","author":"ID Witzel","year":"2008","unstructured":"Witzel ID, M\u00fcller V, Harps E, Janicke F, Dewit M. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol. 2008;19(1):191\u20132. https:\/\/doi.org\/10.1093\/annonc\/mdm542.","journal-title":"Ann Oncol"},{"issue":"2 II","key":"8162_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/01.AOG.0000267133.65430.44","volume":"110","author":"R Sekar","year":"2007","unstructured":"Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol. 2007;110(2 II):507\u201310. https:\/\/doi.org\/10.1097\/01.AOG.0000267133.65430.44.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"8162_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1200\/JCO.2005.04.6607","volume":"24","author":"AM Waterston","year":"2006","unstructured":"Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol. 2006;24(2):321\u20132. https:\/\/doi.org\/10.1200\/JCO.2005.04.6607.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8162_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3816\/CBC.2005.n.040","volume":"6","author":"MA Fanale","year":"2005","unstructured":"Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer. 2005;6(4):354\u20136. https:\/\/doi.org\/10.3816\/CBC.2005.n.040.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"8162_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/01.AOG.0000141570.31218.2b","volume":"105","author":"WJ Watson","year":"2005","unstructured":"Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol. 2005;105(3):642\u20133. https:\/\/doi.org\/10.1097\/01.AOG.0000141570.31218.2b.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"8162_CR37","doi-asserted-by":"publisher","first-page":"NP33","DOI":"10.1177\/0300891620944218","volume":"106","author":"J Berwart","year":"2020","unstructured":"Berwart J, Buonomo B, Peccatori FA, Marioni A, Lescano J, Pressel CE. Management of HER2-positive breast cancer during pregnancy: a case report and literature review. Tumori. 2020;106(6):NP33\u20135. https:\/\/doi.org\/10.1177\/0300891620944218.","journal-title":"Tumori"},{"issue":"01","key":"8162_CR38","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1055\/s-0037-1599133","volume":"07","author":"V Shlensky","year":"2017","unstructured":"Shlensky V, Hallmeyer S, Juarez L, Parilla B. Management of Breast Cancer during pregnancy: are we compliant with current guidelines? Am J Perinatol Rep. 2017;07(01):e39\u201343. https:\/\/doi.org\/10.1055\/s-0037-1599133.","journal-title":"Am J Perinatol Rep"},{"issue":"4","key":"8162_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/CAD.0000000000000344","volume":"27","author":"JM De Andrade","year":"2016","unstructured":"De Andrade JM, Brito LGO, Moises ECD, Amorim AC, Rapatoni L, Carrara HHA, et al. Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up. Anti-Cancer Drugs. 2016;27(4):369\u201372. https:\/\/doi.org\/10.1097\/CAD.0000000000000344.","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"8162_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41416-019-0563-x","volume":"121","author":"N Safi","year":"2019","unstructured":"Safi N, Anazodo A, Dickinson JE, Lui K, Wang AY, Li Z, et al. In utero exposure to breast cancer treatment: a population-based perinatal outcome study. Br J Cancer. 2019;121(8):719\u201321. https:\/\/doi.org\/10.1038\/s41416-019-0563-x.","journal-title":"Br J Cancer"},{"issue":"7","key":"8162_CR41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1080\/14767058.2018.1517308","volume":"33","author":"F Aktoz","year":"2020","unstructured":"Aktoz F, Yalcin AC, Y\u00fczdemir HS, Akata D, G\u00fcltekin M. Treatment of massive liver metastasis of breast cancer during pregnancy: first report of a complete remission with trastuzumab and review of literature. J Matern Neonatal Med. 2020;33(7):1266\u201371. https:\/\/doi.org\/10.1080\/14767058.2018.1517308.","journal-title":"J Matern Neonatal Med"},{"issue":"2","key":"8162_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/cncr.31784","volume":"125","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, et al. Pregnancies during and after trastuzumab and\/or lapatinib in patients with human epidermal growth factor receptor 2\u2013positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019;125(2):307\u201316. https:\/\/doi.org\/10.1002\/cncr.31784.","journal-title":"Cancer"},{"key":"8162_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.14740\/wjon919w","volume":"6","author":"N Pianca","year":"2015","unstructured":"Pianca N, Shafiei M, George M. Trastuzumab exposure in early pregnancy for a young lady with locally invasive breast cancer. World J Oncol. 2015;6:381\u20132. https:\/\/doi.org\/10.14740\/wjon919w.","journal-title":"World J Oncol"},{"issue":"6","key":"8162_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1159\/000335202","volume":"6","author":"I Gottschalk","year":"2011","unstructured":"Gottschalk I, Berg C, Harbeck N, Stressig R, Kozlowski P. Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report und review of the current literature. Breast Care. 2011;6(6):475\u20138. https:\/\/doi.org\/10.1159\/000335202.","journal-title":"Breast Care"},{"issue":"1","key":"8162_CR45","doi-asserted-by":"publisher","first-page":"9329","DOI":"10.1186\/1757-1626-2-9329","volume":"2","author":"MJ Goodyer","year":"2009","unstructured":"Goodyer MJ, Ismail JRM, O\u2019Reilly SP, Moylan EJ, Ryan CAM, Hughes PAF, et al. Safety of trastuzumab (Herceptin\u00ae) during pregnancy: two case reports. Cases J. 2009;2(1):9329. https:\/\/doi.org\/10.1186\/1757-1626-2-9329.","journal-title":"Cases J"},{"issue":"6","key":"8162_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrclinonc.2009.48","volume":"6","author":"HA Azim","year":"2009","unstructured":"Azim HA, Peccatori FA, Liptrott SJ, Catania C, Goldhirsch A. Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol. 2009;6(6):367\u201370. https:\/\/doi.org\/10.1038\/nrclinonc.2009.48.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"8162_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.reprotox.2008.02.002","volume":"25","author":"C Weber-Schoendorfer","year":"2008","unstructured":"Weber-Schoendorfer C, Schaefer C. Letter to the editor. Reprod Toxicol. 2008;25(3):390\u20131. https:\/\/doi.org\/10.1016\/j.reprotox.2008.02.002.","journal-title":"Reprod Toxicol"},{"issue":"4","key":"8162_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.reprotox.2007.02.003","volume":"23","author":"A Shrim","year":"2007","unstructured":"Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Favorable pregnancy outcome following Trastuzumab (Herceptin\u00ae) use during pregnancy-case report and updated literature review. Reprod Toxicol. 2007;23(4):611\u20133. https:\/\/doi.org\/10.1016\/j.reprotox.2007.02.003.","journal-title":"Reprod Toxicol"},{"issue":"1","key":"8162_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1470-2045(06)71014-2","volume":"8","author":"AA Bader","year":"2007","unstructured":"Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 2007;8(1):79\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(06)71014-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8162_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/BD-2009-0289","volume":"31","author":"LS Dominici","year":"2010","unstructured":"Dominici LS, Kuerer HM, Babiera G, Hahn KME, Perkins G, Middleton L, et al. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis. 2010;31(1):1\u20135. https:\/\/doi.org\/10.3233\/BD-2009-0289.","journal-title":"Breast Dis"},{"issue":"5","key":"8162_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5555\/uri:pii:009377548990002X","volume":"16","author":"DC Doll","year":"1989","unstructured":"Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol. 1989;16(5):337\u201346. https:\/\/doi.org\/10.5555\/uri:pii:009377548990002X.","journal-title":"Semin Oncol"},{"issue":"2","key":"8162_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0163-7258(97)82004-9","volume":"74","author":"U Ebert","year":"1997","unstructured":"Ebert U, L\u00f6ffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74(2):207\u201320. https:\/\/doi.org\/10.1016\/S0163-7258(97)82004-9.","journal-title":"Pharmacol Ther"},{"key":"8162_CR53","unstructured":"NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy; NTP Monogr. 2013;(2):i\u2013214. https:\/\/pubmed.ncbi.nlm.nih.gov\/24736875\/."},{"issue":"6","key":"8162_CR54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1586\/eci.10.77","volume":"6","author":"HA Azim","year":"2010","unstructured":"Azim HA, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6(6):821\u20136. https:\/\/doi.org\/10.1586\/eci.10.77.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"8162_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1034\/j.1600-0897.2003.01201.x","volume":"50","author":"P Gurevich","year":"2003","unstructured":"Gurevich P, Elhayany A, Ben-Hur H, Moldavsky M, Szvalb S, Zandbank J, et al. An immunohistochemical study of the secretory immune system in human fetal membranes and decidua of the first trimester of pregnancy. Am J Reprod Immunol. 2003;50(1):13\u20139. https:\/\/doi.org\/10.1034\/j.1600-0897.2003.01201.x.","journal-title":"Am J Reprod Immunol"},{"key":"8162_CR56","unstructured":"HERCEPTIN (trastuzumab) Label \u2013 FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf."},{"issue":"5","key":"8162_CR57","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/BF00852567","volume":"7","author":"PR Goodyer","year":"1993","unstructured":"Goodyer PR, Cybulsky A, Goodyer C. Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol. 1993;7(5):612\u20135. https:\/\/doi.org\/10.1007\/BF00852567.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"8162_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jsgi.2003.09.002","volume":"11","author":"CY Cheung","year":"2004","unstructured":"Cheung CY. Vascular endothelial growth factor activation of intramembranous absorption: a critical pathway for amniotic fluid volume regulation. J Soc Gynecol Investig. 2004;11(2):63\u201374. https:\/\/doi.org\/10.1016\/j.jsgi.2003.09.002.","journal-title":"J Soc Gynecol Investig"},{"issue":"3","key":"8162_CR59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jsgi.2006.02.002","volume":"13","author":"S Wang","year":"2006","unstructured":"Wang S, Amidi F, Beall M, Gui L, Ross MG. Aquaporin 3 expression in human fetal membranes and its up-regulation by cyclic adenosine monophosphate in amnion epithelial cell culture. J Soc Gynecol Investig. 2006;13(3):181\u20135. https:\/\/doi.org\/10.1016\/j.jsgi.2006.02.002.","journal-title":"J Soc Gynecol Investig"},{"issue":"6","key":"8162_CR60","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.ajog.2004.05.089","volume":"191","author":"S Wang","year":"2004","unstructured":"Wang S, Chen J, Beall M, Zhou W, Ross MG. Expression of aquaporin 9 in human chorioamniotic membranes and placenta. Am J Obstet Gynecol. 2004;191(6):2160\u20137. https:\/\/doi.org\/10.1016\/j.ajog.2004.05.089.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"8162_CR61","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1210\/endo.138.3.4991","volume":"138","author":"H Lim","year":"1997","unstructured":"Lim H, Dey SK, Das SK. Differential expression of the erbB2 gene in the periimplantation mouse uterus: potential mediator of signaling by epidermal growth factor-like growth factors. Endocrinology. 1997;138(3):1328\u201337. https:\/\/doi.org\/10.1210\/endo.138.3.4991.","journal-title":"Endocrinology"},{"issue":"1","key":"8162_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-016-3790-3","volume":"157","author":"CM Gallagher","year":"2016","unstructured":"Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, et al. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Res Treat. 2016;157(1):145\u201356. https:\/\/doi.org\/10.1007\/s10549-016-3790-3.","journal-title":"Breast Cancer Res Treat"}],"updated-by":[{"DOI":"10.1186\/s12885-021-09087-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08162-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08162-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08162-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T03:03:07Z","timestamp":1639710187000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08162-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8162"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08162-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-156502\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-021-09087-7","URL":"https:\/\/doi.org\/10.1186\/s12885-021-09087-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAD has received honoraria from participation in advisory boards from Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Takeda. FZ has received honoraria for lectures and has served in an advisory role for Astra-Zeneca, Eli-Lilly, Merck, Novartis, Pfizer, and Roche. The remaining authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"463"}}